. 2021 Feb 9;11:626375. doi: 10.3389/fphar.2020.626375

TABLE 1.

Basic characteristics of included studies.

Study	Sample size	Age (years)	Sex M/F	Intervention measures		Treatment duration (days)	Outcomes	Adverse events
Study	I/C	I/C	I/C	I	C	Treatment duration (days)	Outcomes	Adverse events
He (2015)	40/40	56.20	48/32	D+ACEI or ARB+ARA+β+QSYQ 0.5 g tid	D+ACEI or ARB+ARA+β	180	①③④	None
He and Yang (2019)	60/60	I: 61.40 ± 6.21	I: 38/22	D+ACEI or ARB+β+QSYQ 0.5 g tid	D+ACEI or ARB+β	84	①	Not reported
He and Yang (2019)	60/60	C: 62.21 ± 7.13	C: 36/24	D+ACEI or ARB+β+QSYQ 0.5 g tid	D+ACEI or ARB+β	84	①	Not reported
Hu et al. (2015)	40/40	I: 67.10 ± 5.20	I: 15/25	D+ACEI or ARB+β+QSYQ 0.5 g tid	D+ACEI or ARB+β	56	①③④	None
Hu et al. (2015)	40/40	C: 66.20 ± 6.10	C: 17/23	D+ACEI or ARB+β+QSYQ 0.5 g tid	D+ACEI or ARB+β	56	①③④	None
Li (2014)	40/40	62.30 ± 8.60	—	D+ACEI or ARB+β+QSYQ 0.5 g tid	D+ACEI or ARB+β	90	①②③④⑤	Not reported
Qiu, (2016)	80/80	63.40 ± 9.70	—	D+ACEI or ARB+β+QSYQ 0.5 g tid	D+ACEI or ARB+β	90	①②③④⑤	Not reported
Song (2020)	55/55	I: 63.60 ± 9.20	I: 31/24	D+ACEI or ARB+β+QSYQ 0.5 g tid	D+ACEI or ARB+β	56	①②	Not reported
Song (2020)	55/55	C: 64.80 ± 8.90	C: 30/25	D+ACEI or ARB+β+QSYQ 0.5 g tid	D+ACEI or ARB+β	56	①②	Not reported
Zhang and Li (2013)	49/47	I: 67.00 ± 6.00	—	D+ACEI or ARB+β+QSYQ 0.5 g tid	D+ACEI or ARB+β	180	①③④⑤	None
Zhang and Li (2013)	49/47	C: 68.00 ± 8.00	—	D+ACEI or ARB+β+QSYQ 0.5 g tid	D+ACEI or ARB+β	180	①③④⑤	None
Zhang K. X. et al. (2019)	88/81	I: 70.53 ± 5.28	—	ACEI or ARB+ARA+β+QSYQ 0.5 g tid	ACEI or ARB+ARA+β	180	①⑤	Nausea
Zhang K. X. et al. (2019)	88/81	C: 70.12 ± 6.98	—	ACEI or ARB+ARA+β+QSYQ 0.5 g tid	ACEI or ARB+ARA+β	180	①⑤	Nausea

I, intervention group; C, control group; M, male; F, female; D, diuretic; ARA, aldosterone receptor antagonist; β, β-blocker; QSYQ, Qishen Yiqi Dripping Pill; ① E/A; ② E/e′; ③ BNP; ④ cardiac function improvement rate; ⑤ 6-MWD.